Amylyx Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AMLX and other ETFs, options, and stocks.About AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada.
CEOJoshua B. Cohen
CEOJoshua B. Cohen
Employees123
Employees123
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2013
Founded2013
Employees123
Employees123
AMLX Key Statistics
Market cap1.50B
Market cap1.50B
Price-Earnings ratio-7.60
Price-Earnings ratio-7.60
Dividend yield—
Dividend yield—
Average volume1.10M
Average volume1.10M
High today$14.76
High today$14.76
Low today$13.65
Low today$13.65
Open price$14.29
Open price$14.29
Volume1.01M
Volume1.01M
52 Week high$16.96
52 Week high$16.96
52 Week low$2.60
52 Week low$2.60
Stock Snapshot
The current Amylyx Pharmaceuticals(AMLX) stock price is $13.74, with a market capitalization of 1.5B. The stock trades at a price-to-earnings (P/E) ratio of -7.60.
On 2025-12-09, Amylyx Pharmaceuticals(AMLX) stock moved within a range of $13.65 to $14.76. With shares now at $13.74, the stock is trading +0.7% above its intraday low and -6.9% below the session's peak.
Trading volume for Amylyx Pharmaceuticals(AMLX) stock has reached 1.01M, versus its average volume of 1.1M.
The stock's 52-week range extends from a low of $2.60 to a high of $16.96.
The stock's 52-week range extends from a low of $2.60 to a high of $16.96.
Analyst ratings
100%
of 10 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own AMLX. This list is generated using Robinhood data, and it’s not a recommendation.